Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Arch Capital Group Ltd. Reports 2019 First Quarter Results

Published

on

Reading Time: 13 minutes

PEMBROKE, Bermuda–(BUSINESS WIRE)–Arch Capital Group Ltd. (NASDAQ: ACGL) announces its 2019 first quarter
results. The results included:

  • Net income available to Arch common shareholders of $438.1 million, or
    $1.07 per share, a 19.5% annualized return on average common equity,
    compared to $137.3 million, or $0.33 per share, for the 2018 first
    quarter;
  • After-tax operating income available to Arch common shareholders, a
    non-GAAP measure, of $275.9 million, or $0.67 per share, a 12.3%
    annualized return on average common equity, compared to $235.1
    million, or $0.56 per share, for the 2018 first quarter;
  • Book value per common share of $23.12 at March 31, 2019, a 7.4%
    increase in the 2019 first quarter and a 13.3% increase for the
    trailing twelve months;
  • Pre-tax current accident year catastrophic losses, net of reinsurance
    and reinstatement premiums(1) of $7.9 million;
  • Favorable development in prior year loss reserves, net of related
    adjustments(1) of $36.7 million;
  • Combined ratio excluding catastrophic activity and prior year
    development(1) of 81.4%.

All earnings per share amounts discussed in this release are on a
diluted basis. The following table summarizes the Company’s underwriting
results, both (i) on a consolidated basis and (ii) on a consolidated
basis excluding the ‘other’ segment (i.e., results of Watford Re,
as defined below):

     
(U.S. dollars in thousands) Consolidated Consolidated Excluding ‘Other’ Segment (1)
Three Months Ended March 31, Three Months Ended March 31,
2019   2018   % Change 2019   2018   % Change
Gross premiums written $ 2,077,879 $ 1,838,214 13.0 $ 1,980,453 $ 1,721,605 15.0
Net premiums written 1,525,259 1,412,544 8.0 1,379,872 1,232,992 11.9
Net premiums earned 1,368,866 1,234,899 10.8 1,222,772 1,098,151 11.3
Underwriting income 260,148 236,997 9.8 265,526 237,557 11.8
Underwriting Ratios % Point Change % Point Change
Loss ratio 52.5 % 51.6 % 0.9 49.7 % 49.1 % 0.6
Underwriting expense ratio 29.2 % 29.7 % (0.5 ) 29.3 % 29.7 % (0.4 )
Combined ratio 81.7 % 81.3 % 0.4   79.0 % 78.8 % 0.2  
Combined ratio excluding catastrophic activity and prior year
development
81.4 % 83.2 % (1.8 )
(1)   Excluding the ‘other’ segment. See ‘Comments on Regulation G’ for
further details.
 

Pursuant to GAAP, the Company consolidates the results of Watford
Holdings Ltd. in its financial statements, although it only owns
approximately 11% of Watford Holdings Ltd.’s outstanding common equity.
Watford Holdings Ltd. is the parent of Watford Re Ltd., a multi-line
Bermuda reinsurance company (together with Watford Holdings Ltd.,
“Watford Re”). See ‘Comments on Regulation G’ for further details.

The following table summarizes the Company’s consolidated financial
data, including a reconciliation of net income or loss available to Arch
common shareholders to after-tax operating income or loss available to
Arch common shareholders and related diluted per share results:

   
(U.S. dollars in thousands, except share data) Three Months Ended
March 31,
2019   2018
Net income available to Arch common shareholders $ 438,125 $ 137,276
Net realized (gains) losses (115,644 ) 111,764
Net impairment losses recognized in earnings 1,309 162
Equity in net (income) loss of investment funds accounted for using
the equity method
(46,867 ) (28,069 )
Net foreign exchange (gains) losses (4,994 ) 15,556
Transaction costs and other 1,190 830
Loss on redemption of preferred shares 2,710
Income tax expense (benefit) (1) 2,778   (5,086 )
After-tax operating income available to Arch common shareholders $ 275,897   $ 235,143  
 

Diluted per common share results:

Net income available to Arch common shareholders $ 1.07 $ 0.33
Net realized (gains) losses (0.29 ) 0.26
Net impairment losses recognized in earnings 0.00 0.00
Equity in net (income) loss of investment funds accounted for using
the equity method
(0.11 ) (0.07 )
Net foreign exchange (gains) losses (0.01 ) 0.04
Transaction costs and other 0.00 0.00
Loss on redemption of preferred shares 0.01
Income tax expense (benefit) (1) 0.01   (0.01 )
After-tax operating income available to Arch common shareholders $ 0.67   $ 0.56  
 
Weighted average common shares and common share equivalents
outstanding — diluted
408,971,029 417,893,802
 
Beginning common shareholders’ equity $ 8,659,827 $ 8,324,047
Ending common shareholders’ equity 9,334,596   8,370,372  
Average common shareholders’ equity $ 8,997,212   $ 8,347,210  
 
Annualized return on average common equity 19.5 % 6.6 %
Annualized operating return on average common equity 12.3 % 11.3 %
(1)   Income tax expense on net realized gains or losses, net impairment
losses recognized in earnings, equity in net income (loss) of
investment funds accounted for using the equity method, net foreign
exchange gains or losses, transaction costs and other and loss on
redemption of preferred shares reflects the relative mix reported by
jurisdiction and the varying tax rates in each jurisdiction.
 

Each line item in the table above reflects the impact of the Company’s
approximate 11% ownership of Watford Re’s outstanding common equity. See
‘Comments on Regulation G’ for a discussion of non-GAAP financial
measures.

Segment Information

The following section provides analysis on the Company’s 2019 first
quarter performance by operating segment. For additional details
regarding the Company’s operating segments, please refer to the
Company’s Financial Supplement dated March 31, 2019. The Company’s
segment information includes the use of underwriting income (loss) and a
combined ratio excluding catastrophic activity (if applicable for the
segment) and prior year development. Such items are non-GAAP financial
measures (see ‘Comments on Regulation G’ for further details).

Insurance Segment

    Three Months Ended March 31,
(U.S. dollars in thousands) 2019   2018   % Change
 
Gross premiums written $ 941,954 $ 823,378 14.4
Net premiums written 621,332 576,198 7.8
Net premiums earned 553,505 538,737 2.7
 
Underwriting income $ 562 $ 7,864 (92.9 )
 
Underwriting Ratios % Point Change
Loss ratio 64.4 % 65.7 % (1.3 )
Underwriting expense ratio 35.5 % 32.9 % 2.6  
Combined ratio 99.9 % 98.6 % 1.3  
 
Catastrophic activity and prior year development:
Current accident year catastrophic events, net of reinsurance and
reinstatement premiums
0.0 % 0.2 % (0.2 )
Net (favorable) adverse development in prior year loss reserves, net
of related adjustments
(0.3 )% (0.3 )% 0.0  
Combined ratio excluding catastrophic activity and prior year
development (1)
100.2 % 98.7 % 1.5  
(1)   See ‘Comments on Regulation G’ for further discussion.
 

Gross premiums written by the insurance segment in the 2019 first
quarter were 14.4% higher than in the 2018 first quarter while net
premiums written were 7.8% higher than in the 2018 first quarter. The
increase in net premiums written primarily reflects the acquisition of a
U.K. commercial lines book of business on January 1, 2019, along with
the growth in most lines of business. The percentage increase in gross
premiums written is higher than the increase in net premiums written due
to a single large national account, for which the premium written in the
quarter was substantially ceded. Net premiums earned by the insurance
segment in the 2019 first quarter were 2.7% higher than in the 2018
first quarter, and reflect changes in net premiums written over the
previous five quarters.

The 2019 first quarter loss ratio reflected minimal current year
catastrophic activity, compared to 0.2 points in the 2018 first quarter.
Estimated net favorable development of prior year loss reserves, before
related adjustments, reduced the loss ratio by 0.8 points in the 2019
first quarter, compared to 0.4 points in the 2018 first quarter. The
balance of the change in the 2019 first quarter loss ratio primarily
resulted from changes in mix of business.

The underwriting expense ratio was 35.5% in the 2019 first quarter,
compared to 32.9% in the 2018 first quarter. The increase in the
underwriting expense ratio reflected a previously announced change in
the timing of our incentive compensation practices, with a large portion
of the expense associated with the share based compensation grants
reflected in the 2019 first quarter. In prior periods, share based
compensation grants occurred in the second quarter. On the U.K.
acquisition noted above, only a small portion of net premiums written
were earned in the 2019 first quarter while the Company incurred a full
quarter of expenses. This resulted in a higher expense ratio in the
period, which is expected to moderate as the business matures. The
Company did not acquire any loss reserves or unearned premiums as part
of the transaction.

Reinsurance Segment

    Three Months Ended March 31,
(U.S. dollars in thousands) 2019   2018   % Change
 
Gross premiums written $ 682,855 $ 577,483 18.2
Net premiums written 451,288 381,753 18.2
Net premiums earned 346,365 279,172 24.1
Other underwriting income (loss) 4,377 1,232 255.3
 
Underwriting income $ 20,902 $ 54,839 (61.9 )
 
Underwriting Ratios % Point Change
Loss ratio 69.2 % 50.7 % 18.5
Underwriting expense ratio 26.0 % 30.0 % (4.0 )
Combined ratio 95.2 % 80.7 % 14.5  
 
Catastrophic activity and prior year development:
Current accident year catastrophic events, net of reinsurance and
reinstatement premiums
2.3 % 0.3 % 2.0
Net (favorable) adverse development in prior year loss reserves, net
of related adjustments
0.5 % (13.0 )% 13.5  
Combined ratio excluding catastrophic activity and prior year
development (1)
92.4 % 93.4 % (1.0 )
(1)   See ‘Comments on Regulation G’ for further discussion.
 

Gross and net premiums written by the reinsurance segment in the 2019
first quarter were 18.2% higher than in the 2018 first quarter. The
increase in net premiums written in the 2019 first quarter primarily
reflected growth from selected new business opportunities in casualty
and property excluding property catastrophe. Net premiums earned by the
reinsurance segment in the 2019 first quarter were 24.1% higher than in
the 2018 first quarter, and reflect changes in net premiums written over
the previous five quarters.

The 2019 first quarter loss ratio included 2.3 points of current year
catastrophic activity, compared to 0.4 points of catastrophic activity
in the 2018 first quarter. Estimated net adverse development of prior
year loss reserves, before related adjustments, increased the loss ratio
by 0.5 points in the 2019 first quarter, compared to 13.1 points of
favorable development in the 2018 first quarter. The estimated net
adverse development in the 2019 first quarter included an increase in
reserves on Typhoon Jebi of $16.0 million, or 4.6 points, based on
receipt of updated information from cedents and additional updated
industry data.

The underwriting expense ratio was 26.0% in the 2019 first quarter,
compared to 30.0% in the 2018 first quarter, primarily as a result of
growth in net premiums earned and changes in mix of business.

Mortgage Segment

    Three Months Ended March 31,
(U.S. dollars in thousands) 2019   2018   % Change
 
Gross premiums written $ 356,050 $ 321,178 10.9
Net premiums written 307,252 275,041 11.7
Net premiums earned 322,902 280,242 15.2
Other underwriting income 3,856 3,416 12.9
 
Underwriting income $ 244,062 $ 174,854 39.6
 
Underwriting Ratios % Point Change
Loss ratio 3.5 % 15.5 % (12.0 )
Underwriting expense ratio 22.1 % 23.3 % (1.2 )
Combined ratio 25.6 % 38.8 % (13.2 )
 
Prior year development:
Net (favorable) adverse development in prior year loss reserves, net
of related adjustments
(11.3 )% (4.6 )% (6.7 )
Combined ratio excluding prior year development (1) 36.9 % 43.4 % (6.5 )
(1)   See ‘Comments on Regulation G’ for further discussion.
 

Gross premiums written by the mortgage segment in the 2019 first quarter
were 10.9% higher than in the 2018 first quarter, while net premiums
written were 11.7% higher. The growth in net premiums written primarily
reflected an increase in monthly premiums business due to growth in U.S.
insurance in force, partially offset by a lower level of U.S. single
premium business, a decrease in Australian mortgage reinsurance business
and higher ceded premiums related to Bellemeade transactions. The
increase in net premiums earned for the 2019 first quarter primarily
reflected the growth in insurance in force over the last twelve months,
with $390.4 billion of insurance in force at March 31, 2019, compared to
$349.9 billion at March 31, 2018.

Arch MI U.S. generated $11.2 billion of new insurance written (“NIW”) in
the 2019 first quarter, consistent with the $11.4 billion in the 2018
first quarter. Monthly premium policies contributed 91.6% of NIW in the
2019 first quarter, compared to 91.4% in the 2018 first quarter.

The loss ratio for the 2019 first quarter reflected estimated net
favorable development in prior year loss reserves, before related
adjustments, of 11.3 points in the 2019 first quarter, compared to 4.6
points in the 2018 first quarter. The estimated net favorable
development in the 2019 first quarter was primarily driven by lower
expected claim rates on first lien business and subrogation activity on
second lien business. The percentage of loans in default on first lien
business was 1.54% at March 31, 2019, a decrease from 1.60% at
December 31, 2018 and from 1.98% at March 31, 2018.

The mortgage segment’s underwriting expense ratio was 22.1% in the 2019
first quarter, compared to 23.3% in the 2018 first quarter. The lower
ratio in the 2019 first quarter primarily resulted from the higher level
of net premiums earned.

At March 31, 2019, the mortgage segment’s risk-in-force (before
reinsurance) of $77.1 billion consisted of $71.1 billion from Arch MI
U.S. with the remainder from reinsurance and credit-risk sharing
operations.

Corporate and Non-Underwriting

Corporate and non-underwriting results include net investment income,
other income (loss), corporate expenses, transaction costs and other,
amortization of intangible assets, interest expense, items related to
the Company’s non-cumulative preferred shares, net realized gains or
losses, net impairment losses included in earnings, equity in net income
or loss of investment funds accounted for using the equity method, net
foreign exchange gains or losses and income taxes. Such amounts exclude
the results of the ‘other’ segment.

Pre-tax net investment income for the 2019 first quarter was $0.30 per
share, or $121.2 million, compared to $0.24 per share, or $100.2
million, for the 2018 first quarter. The growth in 2019 first quarter
net investment income reflected the reinvestment of fixed income
securities at higher available yields and the shift from municipal bonds
to corporates. The annualized pre-tax investment income yield was 2.67%
for the 2019 first quarter, compared to 2.13% for the 2018 first
quarter. Total return, a non-GAAP measure, was 2.70% for the 2019 first
quarter, primarily reflecting the decline in interest rates during the
period and attendant appreciation in the Company’s fixed income
portfolio. See ‘Comments on Regulation G’ for a discussion of non-GAAP
financial measures.

Interest expense for the 2019 first quarter was $23.5 million, compared
to $25.9 million for the 2018 first quarter, reflecting the paydown of
revolving credit agreement borrowings in the second half of 2018.

On a pre-tax basis, net foreign exchange gains for the 2019 first
quarter were $5.2 million, compared to net foreign exchange losses for
the 2018 first quarter of $15.0 million. For both periods, such amounts
were primarily unrealized and resulted from the effects of revaluing the
Company’s net insurance liabilities required to be settled in foreign
currencies at each balance sheet date. Changes in the value of
available-for-sale investments held in foreign currencies due to foreign
currency rate movements are reflected as a direct increase or decrease
to shareholders’ equity and are not included in the consolidated
statements of income. Although the Company generally attempts to match
the currency of its projected liabilities with investments in the same
currencies, the Company may elect to over or underweight one or more
currencies from time to time, which could increase the Company’s
exposure to foreign currency fluctuations and increase the volatility of
the Company’s shareholders’ equity.

The Company’s effective tax rate on income before income taxes (based on
the Company’s annual effective tax rate) was 9.3% for the 2019 first
quarter, compared to 12.7% for the 2018 first quarter. The Company’s
effective tax rate on pre-tax operating income available to Arch common
shareholders was 13.1% for the 2019 first quarter, compared to 9.9% for
the 2018 first quarter. The effective tax rates for the 2019 first
quarter included a discrete income tax benefit of $1.8 million related
to share-based compensation. This benefit had the effect of reducing the
effective tax rate on operating income available to Arch common
shareholders by 0.5%. The Company’s effective tax rate may fluctuate
from period to period based upon the relative mix of income or loss
reported by jurisdiction, the level of catastrophic loss activity
incurred, and the varying tax rates in each jurisdiction.

Conference Call

The Company will hold a conference call for investors and analysts at
11:00 a.m. Eastern Time on May 1, 2019. A live webcast of this call will
be available via the Investors section of the Company’s website at http://www.archcapgroup.com.
A telephone replay of the conference call also will be available
beginning on May 1, 2019 at 2:00 p.m. Eastern Time until May 8, 2019 at
midnight Eastern Time. To access the replay, domestic callers should
dial 855-859-2056, and international callers should dial 404-537-3406
(passcode 7196298 for all callers).

Please refer to the Company’s Financial Supplement dated March 31, 2019,
which is available via the Investors section of the Company’s website at http://www.archcapgroup.com.
The Financial Supplement provides additional detail regarding the
financial performance of the Company. From time to time, the Company
posts additional financial information and presentations to its website,
including information with respect to its subsidiaries. Investors and
other recipients of this information are encouraged to check the
Company’s website regularly for additional information regarding the
Company.

Arch Capital Group Ltd., a Bermuda-based company with approximately
$11.85 billion in capital at March 31, 2019, provides insurance,
reinsurance and mortgage insurance on a worldwide basis through its
wholly owned subsidiaries.

Comments on Regulation G

Throughout this release, the Company presents its operations in the way
it believes will be the most meaningful and useful to investors,
analysts, rating agencies and others who use the Company’s financial
information in evaluating the performance of the Company and that
investors and such other persons benefit from having a consistent basis
for comparison between quarters and for comparison with other companies
within the industry. These measures may not, however, be comparable to
similarly titled measures used by companies outside of the insurance
industry. Investors are cautioned not to place undue reliance on these
non-GAAP financial measures in assessing the Company’s overall financial
performance.

This presentation includes the use of “after-tax operating income or
loss available to Arch common shareholders,” which is defined as net
income available to Arch common shareholders, excluding net realized
gains or losses, net impairment losses recognized in earnings, equity in
net income or loss of investment funds accounted for using the equity
method, net foreign exchange gains or losses, transaction costs and
other and loss on redemption of preferred shares, net of income taxes,
and the use of annualized operating return on average common equity. The
presentation of after-tax operating income available to Arch common
shareholders and annualized operating return on average common equity
are non-GAAP financial measures as defined in Regulation G. The
reconciliation of such measures to net income available to Arch common
shareholders and annualized return on average common equity (the most
directly comparable GAAP financial measures) in accordance with
Regulation G is included on the following page of this release.

The Company believes that net realized gains or losses, net impairment
losses recognized in earnings, equity in net income or loss of
investment funds accounted for using the equity method, net foreign
exchange gains or losses, transaction costs and other and loss on
redemption of preferred shares in any particular period are not
indicative of the performance of, or trends in, the Company’s business
performance. Although net realized gains or losses, net impairment
losses recognized in earnings, equity in net income or loss of
investment funds accounted for using the equity method and net foreign
exchange gains or losses are an integral part of the Company’s
operations, the decision to realize investment gains or losses, the
recognition of the change in the carrying value of investments accounted
for using the fair value option in net realized gains or losses, the
recognition of net impairment losses, the recognition of equity in net
income or loss of investment funds accounted for using the equity method
and the recognition of foreign exchange gains or losses are independent
of the insurance underwriting process and result, in large part, from
general economic and financial market conditions. Furthermore, certain
users of the Company’s financial information believe that, for many
companies, the timing of the realization of investment gains or losses
is largely opportunistic. In addition, net impairment losses recognized
in earnings on the Company’s investments represent other-than-temporary
declines in expected recovery values on securities without actual
realization. The use of the equity method on certain of the Company’s
investments in certain funds that invest in fixed maturity securities is
driven by the ownership structure of such funds (either limited
partnerships or limited liability companies). In applying the equity
method, these investments are initially recorded at cost and are
subsequently adjusted based on the Company’s proportionate share of the
net income or loss of the funds (which include changes in the fair value
of the underlying securities in the funds). This method of accounting is
different from the way the Company accounts for its other fixed maturity
securities and the timing of the recognition of equity in net income or
loss of investment funds accounted for using the equity method may
differ from gains or losses in the future upon sale or maturity of such
investments. Transaction costs and other include advisory, financing,
legal, severance, incentive compensation and other costs related to
acquisitions and Watford Re’s non-recurring listing expenses.

Contacts

Arch Capital Group Ltd.
François Morin: (441) 278-9250

Investor Relations
Donald Watson: (914) 872-3616; [email protected]

Read full story here


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Cannabis

Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care

Published

on

Continue Reading

Innocan

Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain

Published

on

innocan-pharma-initiates-fda-approval-process-for-liposome-injection-therapy-for-chronic-pain

With its submission of a Pre-IND Meeting Request Letter, Innocan initiates the regulatory process with the U.S. Food and Drug Administration (FDA) for the approval of its prolonged CBD release technology for human use

HERZLIYA, Israel and CALGARY, AB, April 22, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), is pleased to announce that is has reached a key milestone: the Company submitted its letter of application for a Pre-IND meeting, the first phase in the FDA approval process in the United States for Innocan’s Liposome-Cannabidiol (LPT-CBD) injectable treatment of chronic pain.

With the global market for pain therapeutics widely expected to exceed US$100 billion by 2032[1], LPT therapy which requires only one single monthly subcutaneous injection, is positioned as a highly attractive alternative to opioid-based approaches. Opioids have and continue to take a significant human toll in recent years, with more than three-quarters of drug overdose deaths in the United States involving opioids, according to the United States Center for Disease Control and Prevention[2].

Innocan’s therapy has shown consistent efficacy in multiple pre-clinical trials in recent years of it’s LPT-CBD injectable treatment through prolonged and controlled release of CBD in animals with chronic pain conditions. Innocan’s Pre-IND Meeting Request Letter to the FDA is a key milestone and important first step in seeking approval of its LPT-CBD therapy for use in humans. At the Pre-IND meeting, the objective will be to obtain guidance from the FDA on the preclinical and clinical development plan, enabling the initiation of an Investigational New Drug (IND) program in the United States.

Iris Bincovich, CEO of Innocan, commented: “We are extremely excited to embark on this next stage in the development of LPT-CBD injectables, this is a major Milestone for Innocan Pharma. We have invested significant effort and many thousands of person-hours in its research and development, accumulating a wealth of preclinical data that will serve as the foundation for our participation in the FDA process. This is a key milestone for Innocan and marks our first step towards the FDA’s recognition of our technology. We see significant potential for our therapy, with an addressable market for pain management therapeutics expected to exceed US $100 billion by 2032, and we look forward to tapping that.

Dr. Joseph Pergolizzi, Innocan’s FDA Advisory Board Member, added:

“We have worked hard to catalogue the data collected as part of our animal LPT therapy testing program and prepare it for the FDA. We look forward to working under FDA guidance, with the goal of completing the review process as quickly and efficiently as possible. We believe that Innocan’s unique treatment method, if and when it should become FDA-approved has the potential of being a highly valuable non-opioid addition in the medical arsenal of the management of chronic pain.”

About Innocan

Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies based on advanced cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD- loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for: Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment, Innocan has established a joint venture by the name of BI Sky Global Ltd. that focuses on advanced targeted online sales. https://innocanpharma.com/

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO

+1-516-210-4025

+972-54-3012842

+442037699377
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Cautionary note regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company’s products, requisite regulatory approvals and the timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

[1] https://www.gminsights.com/industry-analysis/pain-management-drugs-market

[2] https://www.cdc.gov/opioids/data/index.html

Logo – https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-initiates-fda-approval-process-for-liposome-injection-therapy-for-chronic-pain-302122779.html

Continue Reading

Curaleaf

Curaleaf Completes Acquisition of Northern Green Canada

Published

on

curaleaf-completes-acquisition-of-northern-green-canada

Bolsters Company’s Advantage in Several Key Emerging Markets, including Australia, New Zealand, Germany, Poland and the United Kingdom

NEW YORK, April 22, 2024 /PRNewswire/ — Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading international provider of consumer cannabis products, announced today the closing of its acquisition of Northern Green Canada (“NGC”), a vertically integrated Canadian licensed cannabis producer focused primarily on expanding in the international market through its EU-GMP certification. The accretive acquisition amplifies the Company’s strategic advantage in established European markets including Germany, Poland and the United Kingdom and provides a foothold in the emerging markets of Australia and New Zealand.

Integrating NGC’s international operation will equip Curaleaf with a secure and consistent high quality, non-irradiated, indoor EU-GMP flower supply, essential to maintaining its leading positions in Germany, the United Kingdom and Poland.

“We are thrilled to welcome NGC formally to the Curaleaf family of global brands,” said Boris Jordan, Founder and Executive Chairman of Curaleaf. “This is an incredibly important deal for our international expansion strategy, as we’ll be able to bolster our supply of high quality EU-GMP certified flower immediately to key European markets as well as enter the fast-growing markets of Australia and New Zealand.”

The global cannabis market is projected to generate $55 billion in sales by 2027. Emerging markets beyond the United States and Canada, including Germany, Australia and New Zealand are expected to contribute $6.3 billion of the $55 billion projection.

Terms of the acquisition of NGC include an initial payment at closing of the Company’s Subordinate Voting Shares valued at approximately US $16 million, subject to a typical post-closing adjustment. An earnout may also be paid in 2025 based upon 2024 performance of NGC’s operations, up to 50% of which will be cash and the rest paid in additional Subordinate Voting Shares. The issuance of Subordinate Voting Shares in connection with the acquisition of NGC has been conditionally approved by the Toronto Stock Exchange, subject to fulfilling customary listing conditions.

About Curaleaf Holdings
Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (“Curaleaf”) is a leading international provider of consumer products in cannabis with a mission to enhance lives by cultivating, sharing and celebrating the power of the plant. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf, Select, Grassroots, JAMS, Find and Zero Proof provide industry-leading service, product selection and accessibility across the medical and adult use markets. Curaleaf International is the largest vertically integrated cannabis company in Europe with a unique supply and distribution network throughout the European market, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf is listed on the Toronto Stock Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit https://ir.curaleaf.com.

Forward Looking Statements
This media advisory contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward–looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans”, “expects” or, “proposed”, “is expected”, “intends”, “anticipates”, or “believes”, or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. More particularly and without limitation, this news release contains forward-looking statements and information concerning the expected benefits of the acquisition of NGC, and the Company’s planned expansion on internal markets, the Company’s anticipated strategic advantages in European markets and emerging markets, the integration of NGC’s internal operations, the anticipated global cannabis market, and the listing of shares issuable in connection with the acquisition on the Toronto Stock Exchange. Such forward-looking statements and information reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company with respect to the matters described in this new release, including the Company’s ability to successfully realize the expected benefits of the acquisition, and the Company’s ability to fulfil the listing conditions imposed by the Toronto Stock Exchange. Forward-looking statements involve risks and uncertainties, which are based on current expectations as of the date of this release and subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including the failure to realize the expected benefits of the acquisition, or the Company’s failure to fulfil the listing conditions imposed by the Toronto Stock Exchange. Additional information about these assumptions and risks and uncertainties is contained under “Risk Factors and Uncertainties” in the Company’s latest annual information form filed on March 6, 2024, which is available under the Company’s SEDAR profile at http://www.sedar.com, and in other filings that the Company has made and may make with applicable securities authorities in the future. Forward-looking statements contained herein are made only as to the date of this press release and we undertake no obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. The Toronto Stock Exchange has not reviewed, approved or disapproved the content of this news release.

INVESTOR CONTACT
Curaleaf Holdings, Inc.
Camilo Lyon, Chief Investment Officer
[email protected]

MEDIA CONTACT
Curaleaf Holdings, Inc.
Tracy Brady, SVP Corporate Communications
[email protected]

View original content:https://www.prnewswire.co.uk/news-releases/curaleaf-completes-acquisition-of-northern-green-canada-302123010.html

Continue Reading

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania